ASX tech rocked a 50pc gain in 2024, Archer Materials shone in December, and Dubber and Brainchip have cashed in on major ...
Neurizon recently received EMA orphan designation for NUZ-001 to treat ALS and filed an FDA IND application to begin a phase ...
Dr Boreham’s Crucible: This cancer-tackling, cell-therapy player might just have a fighting chance
Cell therapies have suffered from hyped-up expectations, clinical setbacks and high costs. But maybe, just maybe, Arovella is ...
Stockhead delves into Elevate Uranium, a company advancing its uranium assets in Namibia, utilising its patented U-pgrade process.
Ads for AI-related roles are shrinking in Australia, new job data reveals, with the number down 35 per cent compared to over ...
Aussies are missing out on hundreds of thousands of dollars in superannuation returns, according to one of the nation’s largest super funds.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback